FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110067379> ?p ?o ?g. }

• W2110067379 endingPage "661" @default.
• W2110067379 startingPage "652" @default.
• W2110067379 abstract "In a phase I trial the toxicity and immunomodulatory effects of combined treatment with intravenous (i.v.) bispecific monoclonal antibody BIS-1 and subcutaneous (s.c.) interleukin 2 (IL-2) was studied in renal cell cancer patients. BIS-1 combines a specificity against CD3 on T lymphocytes with a specificity against a 40 kDa pancarcinoma-associated antigen, EGP-2. Patients received BIS-1 F(ab')2 fragments intravenously at doses of 1, 3 and 5 micrograms kg-1 body weight during a concomitantly given standard s.c. IL-2 treatment. For each dose, four patients were treated with a 2 h BIS-1 infusion in the second and fourth week of IL-2 therapy. Acute BIS-1 F(ab')2-related toxicity with symptoms of chills, peripheral vasoconstriction and temporary dyspnoea was observed in 2/4 and 5/5 patients at the 3 and 5 micrograms kg-1 dose level respectively. The maximum tolerated dose (MTD) of BIS-1 F(ab')2 was 5 micrograms kg-1. Elevated plasma levels of tumour necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) were detected at the MTD. Flow cytometric analysis showed a dose-dependent binding of BIS-1 F(ab')2 to circulating T lymphocytes. Peripheral blood mononuclear cells (PBMCs), isolated after treatment with 3 and 5 micrograms kg-1 BIS-1, showed increased specific cytolytic capacity against EGP-2+ tumour cells as tested in an ex vivo performed assay. Maximal killing capacity of the PBMCs, as assessed by adding excess BIS-1 to the assay, was shown to be decreased after BIS-1 infusion at 5 micrograms kg-1 BIS-1 F(ab')2. A BIS-1 F(ab')2 dose-dependent disappearance of circulating mononuclear cells from the peripheral blood was observed. Within the circulating CD3+ CD8+ lymphocyte population. LFA-1 alpha-bright and HLA-DR+ T-cell numbers decreased preferentially. It is concluded that i.v. BIS-1 F(ab')2, when combined with s.c. IL-2, has a MTD of 5 micrograms kg-1. The treatment endows the T lymphocytes with a specific anti-EGP-2-directed cytotoxic potential." @default.
• W2110067379 created "2016-06-24" @default.
• W2110067379 creator A5003398874 @default.
• W2110067379 creator A5007063744 @default.
• W2110067379 creator A5023786821 @default.
• W2110067379 creator A5049142517 @default.
• W2110067379 creator A5049603142 @default.
• W2110067379 creator A5052535324 @default.
• W2110067379 creator A5084179687 @default.
• W2110067379 creator A5088842293 @default.
• W2110067379 date "1994-10-01" @default.
• W2110067379 modified "2023-10-06" @default.
• W2110067379 title "Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2" @default.
• W2110067379 cites W1493845674 @default.
• W2110067379 cites W1500793474 @default.
• W2110067379 cites W1505037861 @default.
• W2110067379 cites W1542095657 @default.
• W2110067379 cites W1563434511 @default.
• W2110067379 cites W1902748641 @default.
• W2110067379 cites W1914396593 @default.
• W2110067379 cites W1941703268 @default.
• W2110067379 cites W1942232650 @default.
• W2110067379 cites W1968694221 @default.
• W2110067379 cites W1973443459 @default.
• W2110067379 cites W1975568557 @default.
• W2110067379 cites W1976969042 @default.
• W2110067379 cites W1983394829 @default.
• W2110067379 cites W2001968719 @default.
• W2110067379 cites W2023236831 @default.
• W2110067379 cites W2025260365 @default.
• W2110067379 cites W2029432061 @default.
• W2110067379 cites W2048025181 @default.
• W2110067379 cites W2059587428 @default.
• W2110067379 cites W2063538678 @default.
• W2110067379 cites W2065621206 @default.
• W2110067379 cites W2070216352 @default.
• W2110067379 cites W2070618589 @default.
• W2110067379 cites W2071289748 @default.
• W2110067379 cites W2080837403 @default.
• W2110067379 cites W2080929779 @default.
• W2110067379 cites W2093830420 @default.
• W2110067379 cites W2108391599 @default.
• W2110067379 cites W2132331648 @default.
• W2110067379 cites W2133254496 @default.
• W2110067379 cites W2136045513 @default.
• W2110067379 cites W2141033298 @default.
• W2110067379 cites W2146457529 @default.
• W2110067379 cites W2149875662 @default.
• W2110067379 cites W2165919275 @default.
• W2110067379 cites W2331827162 @default.
• W2110067379 cites W2437172426 @default.
• W2110067379 cites W339499435 @default.
• W2110067379 doi "https://doi.org/10.1038/bjc.1994.366" @default.
• W2110067379 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2033411" @default.
• W2110067379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7917912" @default.
• W2110067379 hasPublicationYear "1994" @default.
• W2110067379 type Work @default.
• W2110067379 sameAs 2110067379 @default.
• W2110067379 citedByCount "79" @default.
• W2110067379 countsByYear W21100673792012 @default.
• W2110067379 countsByYear W21100673792014 @default.
• W2110067379 countsByYear W21100673792015 @default.
• W2110067379 countsByYear W21100673792016 @default.
• W2110067379 countsByYear W21100673792020 @default.
• W2110067379 countsByYear W21100673792021 @default.
• W2110067379 countsByYear W21100673792022 @default.
• W2110067379 countsByYear W21100673792023 @default.
• W2110067379 crossrefType "journal-article" @default.
• W2110067379 hasAuthorship W2110067379A5003398874 @default.
• W2110067379 hasAuthorship W2110067379A5007063744 @default.
• W2110067379 hasAuthorship W2110067379A5023786821 @default.
• W2110067379 hasAuthorship W2110067379A5049142517 @default.
• W2110067379 hasAuthorship W2110067379A5049603142 @default.
• W2110067379 hasAuthorship W2110067379A5052535324 @default.
• W2110067379 hasAuthorship W2110067379A5084179687 @default.
• W2110067379 hasAuthorship W2110067379A5088842293 @default.
• W2110067379 hasBestOaLocation W21100673792 @default.
• W2110067379 hasConcept C126322002 @default.
• W2110067379 hasConcept C137061746 @default.
• W2110067379 hasConcept C185592680 @default.
• W2110067379 hasConcept C202751555 @default.
• W2110067379 hasConcept C203014093 @default.
• W2110067379 hasConcept C2777371288 @default.
• W2110067379 hasConcept C2778594517 @default.
• W2110067379 hasConcept C2778690821 @default.
• W2110067379 hasConcept C2780841837 @default.
• W2110067379 hasConcept C29730261 @default.
• W2110067379 hasConcept C55493867 @default.
• W2110067379 hasConcept C71924100 @default.
• W2110067379 hasConcept C90924648 @default.
• W2110067379 hasConcept C98274493 @default.
• W2110067379 hasConceptScore W2110067379C126322002 @default.
• W2110067379 hasConceptScore W2110067379C137061746 @default.
• W2110067379 hasConceptScore W2110067379C185592680 @default.
• W2110067379 hasConceptScore W2110067379C202751555 @default.
• W2110067379 hasConceptScore W2110067379C203014093 @default.
• W2110067379 hasConceptScore W2110067379C2777371288 @default.
• W2110067379 hasConceptScore W2110067379C2778594517 @default.

• next